Abstract:China Kadoorie Biobank is a population-based prospective cohort of >512,000 adults recruited in 2004-2008 from 10 geographically diverse regions across China. Detailed data from questionnaire and physical measurements were collected at baseline, with additional measurements at three resurveys involving approximately 5% of surviving participants. Incident disease events are captured through electronic linkage to death and disease registries and to the national health insurance system. Genome-wide genotyping has been conducted for >100,000 participants using custom-designed Axiom® arrays. Analysis of these data reveals extensive relatedness within the CKB cohort, signatures of recent consanguinity, and principal component signatures reflecting large-scale population movements from recent Chinese history. In addition to numerous CKB studies of candidate drug targets and disease risk factors, CKB has made substantial contributions to many international genetics consortia. Collected biosamples are now being used for high-throughput ‘omics assays which, together with planned whole genome sequencing, will continue to enhance the scientific value of this biobank. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. Long-term follow-up was supported by the Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z), the National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904), and the National Natural Science Foundation of China (91843302). DNA extraction and genotyping was funded by GlaxoSmithKline, and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). The project is supported by core funding from the UK Medical Research Council (MC\_UU\_00017/1, MC\_UU\_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186; C500/A16896), and the British Heart Foundation (CH/1996001/9454) to the Clinical Trial Service Unit and Epidemiological Studies Unit and to the MRC Population Health Research Unit at Oxford University. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Oxford Tropical Research Ethics Committee of University of Oxford gave ethical approval for this work. Ethical Review Committees of the Chinese Centre for Disease Control and Prevention, Chinese Academy of Medical Sciences gave ethical approval for this work. Institutional Review Board (IRB) at Peking University gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Data from baseline, first and second resurveys, and disease follow-up are available under the CKB Open Access Data Policy to bona fide researchers. Sharing of genotyping data is currently constrained by the Administrative Regulations on Human Genetic Resources of the People's Republic of China. Access to these and certain other data is available through collaboration with CKB researchers. Full details of the CKB Data Sharing Policy are available at [www.ckbiobank.org][1]. [1]: http://www.ckbiobank.org

Construction and Application of Human Genetic Resources in the China Kadoorie Biobank.

Plenary XI Epidemiology and the Control of Disease in China, with Emphasis on the Chinese Biobank (KSCDC) Project

Genotyping and population characteristics of the China Kadoorie Biobank

Construction and Utilization of Human Genetic Resources in Large Population Cohorts.

[The China Kadoorie Biobank: Related Methodology and Baseline Characteristics of the Participants].

Genotyping and population structure of the China Kadoorie Biobank

Human disease biobanking in China:results from a primary survey and perspectives

A comprehensive repository of mutation data and a clinical assistant decision system for hemoglobinopathy in the Chinese population

A high-resolution haplotype-resolved Reference panel constructed from the China Kadoorie Biobank Study

The design and implementation of natural population cohort study Biobank: A multiple-center project cooperation with medical consortia in Southwest China

Using Big Data to Improve Cardiovascular Care and Outcomes in China: a Protocol for the CHinese Electronic Health Records Research in Yinzhou (CHERRY) Study

[The Breast Cancer Cohort Study in Chinese Women: the construction and progress of the pan-shared biobank]

Release of the National Healthcare Big Data in China: a Historic Leap in Clinical Research

Research on Biobank Construction and Governance in China

Biobanks and Cancer Genome Projects in China

[Associations of Lifestyles with Major Chronic Diseases in Chinese Adults: Evidence from the China Kadoorie Biobank].

[Chinese Human Genome Project--opportunity and Challenge].

Ten Years of the Cohort Biobank: Bibliometric Outcomes.

Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease

China: public health genomics.